The favorable prognosis group includes AMLs with acute promyelocytic leukemia (APL) t(15;17), balanced translocations t(8;21), biallelic mutated CEBPA and inv(16), and mutated NPM1 without FLT3-ITD. Here, NPM1 is linked to acute promyelocytic leukemia.